Viatris Settles with Henrietta Lacks Estate Over Cell Use Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy VTRS?
Source: seekingalpha
- Settlement Reached: Viatris has settled with the estate of Henrietta Lacks to resolve allegations of using her cancer cells without permission, indicating the company's proactive approach to mitigate legal disputes and avoid further litigation.
- Lawsuit Concluded: The settlement resolves the case with prejudice, meaning similar claims cannot be refiled, which reduces future legal risks and protects the company's reputation in the healthcare sector.
- Family Satisfaction: A lawyer for Lacks' estate expressed that the family is pleased with the resolution, reflecting a compromise that may serve as a precedent for future settlements with other healthcare companies.
- Biomedical Research Impact: Since 1951, Lacks' cell line has been a cornerstone in biopharma research, and Viatris' settlement may prompt the company to enhance ethical compliance management to maintain its reputation and market position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to rise
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 13.050
Low
10.00
Averages
13.25
High
16.00
Current: 13.050
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor® SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare, becoming the first and only approved treatment for adults with generalized anxiety disorder (GAD) in Japan, addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Market Demand Response: With approximately 7.6% of the Japanese population potentially suffering from GAD, this approval not only provides a new treatment option for patients but also has the potential to reduce social and occupational impairments caused by anxiety, thereby enhancing overall societal productivity.
- Clinical Trial Success: The approval of Effexor® is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated significant anxiolytic effects of venlafaxine compared to placebo at 8 weeks, as measured by the Hamilton Anxiety Rating Scale (HAM-A), with all seven secondary efficacy endpoints met.
- Strategic Investment and Expansion: This approval marks the successful execution of Viatris' innovative product portfolio strategy in Japan, and the company plans to leverage its deep expertise in central nervous system therapies to further expand its market presence and meet urgent patient needs.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor®SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare as the first and only treatment option for adults with generalized anxiety disorder (GAD), addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Successful Clinical Trials: The approval is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated that Effexor® significantly outperformed placebo over 8 weeks, achieving statistical significance in the change of Hamilton Anxiety Rating Scale total score (p-value=0.012), providing a solid foundation for market promotion.
- Huge Market Potential: With a reported GAD prevalence of 7.6% in Japan, the demand for this medication is substantial, and Viatris plans to leverage its deep expertise in central nervous system therapies to enhance Effexor®'s market penetration and strengthen its competitive position in the mental health sector.
- Strategic Investment and Innovation: This approval aligns with Viatris' innovative product portfolio in Japan, showcasing the company's strategic execution in addressing unmet medical needs, and it will continue to drive the development of more innovative therapies to tackle health challenges in the Japanese market.
See More
Viatris Sets Long-Term Financial Targets Through 2030
- Long-Term Financial Goals: Viatris (VTRS) aims for a total revenue CAGR of 5%-6% through 2030, with adjusted EBITDA and EPS growth projected at 7%-8% and 9%-10%, respectively, reflecting the company's confidence in future growth.
- Base Business Forecast: For its base business, Viatris anticipates a total revenue CAGR of 3%-4%, adjusted EBITDA of 4%-5%, and adjusted EPS of 6%-7%, providing a solid foundation for sustainable growth.
- Cost Savings Initiative: The company expects to achieve $650 million in gross cost savings over three years from a recently completed enterprise-wide strategic review, which will support adjusted EBITDA growth through operational leverage.
- Cash Flow Outlook: Viatris projects over $2.7 billion in annual free cash flow by 2030 and more than $11 billion in cash available for deployment through 2030, indicating strong financial flexibility and investment potential.
See More
Viatris Unveils Strategic Vision for 2030 Growth
- Strategic Vision Articulation: During the investor event, CEO Scott A. Smith emphasized that Viatris aims to drive sustained revenue and earnings growth through 2030 by simplifying its product portfolio and enhancing financial flexibility, reflecting the company's confidence in future development.
- Financial Target Setting: Viatris anticipates achieving a 5% to 6% compound annual growth rate (CAGR) in total revenues by 2030, along with over $3 billion in annual free cash flow, indicating a strategic approach to capital allocation and business development.
- Cost Savings Initiative: In its recently completed enterprise-wide strategic review, Viatris identified approximately $650 million in gross cost savings, with up to $250 million expected to be reinvested, further enhancing the company's competitive position in the market.
- Cash Flow Outlook: Viatris expects to have over $11 billion in cash available for deployment by 2030, providing robust support for shareholder returns and accretive business development, showcasing its financial resilience in the industry.
See More
Viatris Unveils Long-Term Financial Targets Through 2030
- Long-Term Financial Targets: Viatris anticipates achieving a total revenue CAGR of 5% to 6%, an adjusted EBITDA CAGR of 7% to 8%, and an adjusted EPS CAGR of 9% to 10% by 2030, alongside a projected annual free cash flow exceeding $3 billion, reflecting strong confidence in future growth.
- Cash Flow and Capital Return: The company expects to have over $11 billion in cash available for investment and capital return by 2030, enabling it to pursue accretive business development while maintaining financial flexibility, thereby enhancing its long-term growth profile.
- Product Launch Plans: Viatris plans to launch fast-acting meloxicam and low-dose estrogen weekly patches in the U.S., as well as Pitolisant and Effexor® in Japan, with these upcoming products expected to significantly boost revenue and strengthen its market position.
- Strategic Development and Cost Savings: Through its recently completed Enterprise-Wide Strategic Review, Viatris identified approximately $650 million in gross cost savings, with up to $250 million expected to be reinvested in the company, which not only enhances operational efficiency but also provides funding for future innovations and market expansion.
See More
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor® SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare, becoming the first and only approved treatment for adults with generalized anxiety disorder (GAD) in Japan, addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Market Demand Response: With approximately 7.6% of the Japanese population potentially suffering from GAD, this approval not only provides a new treatment option for patients but also has the potential to reduce social and occupational impairments caused by anxiety, thereby enhancing overall societal productivity.
- Clinical Trial Success: The approval of Effexor® is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated significant anxiolytic effects of venlafaxine compared to placebo at 8 weeks, as measured by the Hamilton Anxiety Rating Scale (HAM-A), with all seven secondary efficacy endpoints met.
- Strategic Investment and Expansion: This approval marks the successful execution of Viatris' innovative product portfolio strategy in Japan, and the company plans to leverage its deep expertise in central nervous system therapies to further expand its market presence and meet urgent patient needs.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor®SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare as the first and only treatment option for adults with generalized anxiety disorder (GAD), addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Successful Clinical Trials: The approval is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated that Effexor® significantly outperformed placebo over 8 weeks, achieving statistical significance in the change of Hamilton Anxiety Rating Scale total score (p-value=0.012), providing a solid foundation for market promotion.
- Huge Market Potential: With a reported GAD prevalence of 7.6% in Japan, the demand for this medication is substantial, and Viatris plans to leverage its deep expertise in central nervous system therapies to enhance Effexor®'s market penetration and strengthen its competitive position in the mental health sector.
- Strategic Investment and Innovation: This approval aligns with Viatris' innovative product portfolio in Japan, showcasing the company's strategic execution in addressing unmet medical needs, and it will continue to drive the development of more innovative therapies to tackle health challenges in the Japanese market.
See More
Viatris Sets Long-Term Financial Targets Through 2030
- Long-Term Financial Goals: Viatris (VTRS) aims for a total revenue CAGR of 5%-6% through 2030, with adjusted EBITDA and EPS growth projected at 7%-8% and 9%-10%, respectively, reflecting the company's confidence in future growth.
- Base Business Forecast: For its base business, Viatris anticipates a total revenue CAGR of 3%-4%, adjusted EBITDA of 4%-5%, and adjusted EPS of 6%-7%, providing a solid foundation for sustainable growth.
- Cost Savings Initiative: The company expects to achieve $650 million in gross cost savings over three years from a recently completed enterprise-wide strategic review, which will support adjusted EBITDA growth through operational leverage.
- Cash Flow Outlook: Viatris projects over $2.7 billion in annual free cash flow by 2030 and more than $11 billion in cash available for deployment through 2030, indicating strong financial flexibility and investment potential.
See More
Viatris Unveils Strategic Vision for 2030 Growth
- Strategic Vision Articulation: During the investor event, CEO Scott A. Smith emphasized that Viatris aims to drive sustained revenue and earnings growth through 2030 by simplifying its product portfolio and enhancing financial flexibility, reflecting the company's confidence in future development.
- Financial Target Setting: Viatris anticipates achieving a 5% to 6% compound annual growth rate (CAGR) in total revenues by 2030, along with over $3 billion in annual free cash flow, indicating a strategic approach to capital allocation and business development.
- Cost Savings Initiative: In its recently completed enterprise-wide strategic review, Viatris identified approximately $650 million in gross cost savings, with up to $250 million expected to be reinvested, further enhancing the company's competitive position in the market.
- Cash Flow Outlook: Viatris expects to have over $11 billion in cash available for deployment by 2030, providing robust support for shareholder returns and accretive business development, showcasing its financial resilience in the industry.
See More
Viatris Unveils Long-Term Financial Targets Through 2030
- Long-Term Financial Targets: Viatris anticipates achieving a total revenue CAGR of 5% to 6%, an adjusted EBITDA CAGR of 7% to 8%, and an adjusted EPS CAGR of 9% to 10% by 2030, alongside a projected annual free cash flow exceeding $3 billion, reflecting strong confidence in future growth.
- Cash Flow and Capital Return: The company expects to have over $11 billion in cash available for investment and capital return by 2030, enabling it to pursue accretive business development while maintaining financial flexibility, thereby enhancing its long-term growth profile.
- Product Launch Plans: Viatris plans to launch fast-acting meloxicam and low-dose estrogen weekly patches in the U.S., as well as Pitolisant and Effexor® in Japan, with these upcoming products expected to significantly boost revenue and strengthen its market position.
- Strategic Development and Cost Savings: Through its recently completed Enterprise-Wide Strategic Review, Viatris identified approximately $650 million in gross cost savings, with up to $250 million expected to be reinvested in the company, which not only enhances operational efficiency but also provides funding for future innovations and market expansion.
See More
